Vemurafenid and Dabrafenid or Trametinib, BRAF-mutant inhibitors approved by the FDA for the treatment of BRAF-V600-mutated-melanoma, have reported remission in 90% of patients (22). The gene discussed is BRAF; the disease is melanoma.